Belgium· BE-AMP-SAM595911-00
Skytrofa 3.6 mg
A lonapegsomatropin product containing lonapegsomatropin, registered in Belgium by Ascendis Pharma Endocrinology Division. The same ATC class is registered in 8 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Lonapegsomatropin is registered in 8 of 19 countries.
Countries holding a registration under ATC H01AC09 (lonapegsomatropin), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 5 of them publish a price we can compare per daily dose
Lonapegsomatropin · ATC H01AC09
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Lonapegsomatropin
- Manufacturer
- Ascendis Pharma Endocrinology Division
- Country
- Belgium (BE)
- ATC code
- H01AC09
- ATC class
- Lonapegsomatropin
- Defined daily dose
- 0.9 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lonapegsomatropin in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandSkytrofaAscendis Pharma Endocrinology Division A/S
- SwedenSkytrofa 3,6 mg Pulver och vätska till injektionsvätska, lösning i cylinderampullAscendis Pharma Endocrinology Division A/S
- United StatesSkytrofaAscendis Pharma Endocrinology, Inc.
- FinlandSkytrofaAscendis Pharma Endocrinology Division A/S
- NetherlandsSkytrofa 11 mg, poeder en oplosmiddel voor oplossing voor injectie in een patroonAscendis Pharma Endocrinology Division A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Skytrofa
- Liechtenstein · Skytrofa
- Norway · Skytrofa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ccabf321-e751-45a6-975a-d9b3d2027a48 GET /v1/drugs/ccabf321-e751-45a6-975a-d9b3d2027a48?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder and solvent for solution for injection in cartridge",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Skytrofa 3.6 mg",
"name_fr": "Skytrofa 3.6 mg",
"name_nl": "Skytrofa 3.6 mg",
"amp_code": "SAM595911-00",
"strengths": [
"10.3000",
"10.3000",
"3.6000",
"3.6000"
],
"pack_count": 1,
"substances": [
"Lonapegsomatropin",
"Somatropin"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Lonapegsomatropin",
"authorisation_numbers": [
"EU/1/21/1607/002"
]
}See everything about lonapegsomatropin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.